Researchers in Dana-Farber’s Center for Neuro-Oncology are now launching attacks on glioblastomas from a new angle – by turning the patient’s immune system against the cancer cells. Where targeted chemotherapy uses drugs to disable proteins that cancer cells need to grow, immunotherapy drugs stimulate the patient’s immune system to recognize and […]
Immunotherapy, treatments for ovarian cancer, and investigating game-changing drug therapies topped the list of the most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014. Here are some highlights from the last year in research: Hodgkin lymphoma Some of the most dramatic evidence of potential of immunotherapies […]
In the treatment of blood cancers and disorders, doctors and researchers are focusing their sights on the immune system and how to bolster its ability to fight off diseases like leukemia, lymphoma and multiple myeloma. “Understanding how you control the immune system is a big theme in treatment for these […]
In the 1940s, children diagnosed with leukemia had a grim prognosis; there was essentially nothing doctors could offer to treat the young patients, other than cortisone therapy to help with side effects of the disease. But in 1948, Dana-Farber founder Sidney Farber, MD, believed a drug that blocked folic acid would shut down […]
Lung cancer, which causes more deaths worldwide than any other malignancy, is revealing its vulnerabilities under a sustained assault from science. Many of the most recent advances against the disease have a long pedigree at Dana-Farber. It was 10 years ago, in fact, that Dana-Farber scientists and elsewhere showed non-small […]
Twenty years ago, scientists announced the discovery of BRCA1, which arguably has become the best-known cancer susceptibility gene in the world. When inherited in a mutated form, the gene sharply increases a woman’s chances of developing breast or ovarian cancer, often at an early age. The discovery has changed the […]
The Food and Drug Administration has approved a new type of immunotherapy drug that will provide a much-needed option for patients with advanced or inoperable melanoma who no longer respond to other drugs – including the immunotherapy agent ipilimumab (Yervoy). The drug, pembrolizumab or MK-3745, will be marketed under the name Keytruda. Based on […]
A new national guideline for the treatment of women with a type of advanced breast cancer known as HER2-negative disease balances state-of-the-art evidence with a need to tailor therapy to each patient’s circumstances and preferences. The guideline, developed by a panel of experts convened by the American Society of Clinical […]
Head and neck cancers account for 3 to 5 percent of all cancers in the United States and can occur in the oral and nasal cavities, the sinuses, the throat, the larynx, the salivary glands, and the thyroid. When diagnosed early, many head and neck cancers can be cured with […]
Cancer genetics has come a long way in the last two decades, leading to increased prevention and improved treatment options. Today, research is shining the light on why certain people have an increased risk for cancer. “It took us 20 years to get where we are today with the knowledge […]
Research by Dana-Farber Cancer Institute scientists supports the U.S. Food and Drug Administration’s recent warning about laparoscopic power morcellation, a procedure sometimes used to remove the uterus and uterine fibroids, noncancerous growths that often appear during childbearing years. The FDA based its warning on data suggesting that the procedure may […]
Multiple myeloma is one of the most compelling examples of a cancer in which research has markedly improved the length and quality of patients’ lives in the last decade. A malignancy of certain white blood cells in the bone marrow known as plasma cells, myeloma is still considered incurable, but treatment […]
“Science and Society” was the theme of this year’s American Society of Clinical Oncology (ASCO) 50th annual meeting. The meeting showcased cancer research from around the world. Some new findings from Dana-Farber researchers included: Joyce Liu, MD, MPH, of the Susan F. Smith Center for Women’s Cancers reported that, in […]
The fight against cancers of the digestive system – including colorectal, stomach, esophageal, hepatic, and pancreatic cancers – has made significant progress in the past 50 years, especially in prevention and early diagnosis of colorectal cancer, where screening with tests such as colonoscopies is continuing to make a major impact. “In […]
Nearly all cancer drugs in use today were developed through clinical trials. But before they are approved for use, they must go through multiple phases designed to test the drug’s safety and efficacy. These phases include preclinical, phase I, II, and III. In phase I clinical trials, investigators evaluate how […]
With new approaches to therapy and increased understanding of the biology of cancer, breast cancer treatment has made significant progress in recent years. “I am personally very excited about what’s to come for breast cancer treatment,” says Eric Winer, MD, director of the Breast Oncology Program in the Susan F. […]
Women with hormone receptor-positive (HR+) breast cancer should be given the option to have adjuvant hormonal therapy for as long as 10 years, according to new guidelines issued today by the American Society of Clinical Oncology (ASCO). The updated guidelines reflect results from several large studies that showed women who […]
Every year, about 4,700 children in the United States are diagnosed with brain cancer – making it the most common solid tumor in children. It is also one of the most difficult cancers to treat. Brain tumors are the leading cause of cancer-related deaths in children under age 10 and […]
Middle East Respiratory Syndrome (MERS), a viral respiratory illness has been in the news a lot lately. MERS, first detected in Saudia Arabia in 2012, is caused by a coronavirus called “Middle East Respiratory Syndrome Coronavirus” (MERS-CoV). It isn’t known exactly where the virus comes from though many infectious disease […]
Ten years ago researchers at Dana-Farber and in Japan published a study showing that lung cancer patients whose tumors had a malfunctioning version of a protein called Epidermal Growth Factor Receptor (EGFR) responded dramatically to a drug that specifically targets the EGFR protein. The findings launched the era of precision […]
If the new era of “targeted” cancer drugs and personalized treatments for patients realizes its promise, the power of genomics will get a lot of the credit. Genomics is one of the most commonly heard terms in cancer research and biotech companies today – but what does it really mean? […]
Reports of an experimental drug that slowed advanced breast cancer in a clinical trial have stirred excitement at a national research meeting and breathed new life into a cancer-fighting strategy that had seemed to falter. In one study, the drug, palbociclib, doubled the length of time without disease progression in […]
It’s been suggested that regular use of talcum powder products in the genital area might increase the possibility of ovarian cancer. In theory, particles of talc could travel through the reproductive tract to the ovaries and cause cancer. Research on this potential link has yielded mixed findings, with some studies […]
A young woman in her prime, with a full life and meaningful career, does not expect a cancer diagnosis. But that is what happened to 34-year-old Erin, who received the news when she was in Paris with her mother and sister, on a long-awaited trip to celebrate Mother’s Day.
By Tom Ulrich One of the hot trends in drug discovery could be called drug re-discovery: finding new uses for drugs that have already received FDA approval for a different indication. It’s an approach that allows researchers and clinicians to rapidly test potential treatments for rare or difficult-to-treat conditions. Because […]
The Food and Drug Administration’s recent approval of the drug ibrutinib offers a major new option for patients with chronic lymphocytic leukemia (CLL) who tried at least one prior therapy, physicians say.
Cancers of the vulva – the external portion of the female genitals – are diagnosed in approximately 4,700 women in the United States each year. While many patients can be cured by a combination of surgery, chemotherapy, and radiation therapy, others – particularly those whose cancer has metastasized to other […]
A Food and Drug Administration (FDA) panel has recommended that a DNA test should be the primary screening tool for cervical cancer, rather than the traditional Pap smear. The DNA test detects the DNA of human papillomavirus (HPV), the sexually transmitted infection that causes almost all cases of cervical cancer. […]
The number of deaths from breast cancer has dropped over the past decade in the United States, but around the world, especially in less-developed countries, the number is rising. A report from the World Health Organization (WHO) in December 2013 said 522,000 women died from breast cancer in 2012 – […]
Outcomes are gradually improving for patients who suffer from graft-versus-host disease (GVHD), one of the most serious complications of stem cell transplantation, and researchers are optimistic that further advances may be on the way.
Not long ago, a diagnosis of multiple myeloma — a cancer of the bone marrow — carried with it a very poor prognosis, with median survival estimates of just two to three years. Now, thanks in large part to research and treatment advances at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), […]
In prostate cancer – the most common cancer in men aside from skin cancer – scientists are working to answer some of the most basic questions about the disease while developing an array of new treatments. Using the prostate-specific antigen (PSA) blood test, doctors are often able to detect prostate […]
NBC News’ Tom Brokaw, 74, revealed this week he has multiple myeloma, a cancer of the bone marrow. The disease, also known as plasma cell myeloma, will be diagnosed in more than 24,000 Americans this year.
Immunotherapy – stimulating the body’s defenses to recognize and destroy disease-causing cells and proteins – was dubbed the “breakthrough of the year” in 2013 by Science magazine. Dana-Farber researchers have contributed many important discoveries over the years about how the immune system works. Now, they are building on these insights […]
When cancer develops in someone with other diseases, it can be more serious, according to a recent annual report from several national cancer organizations. “Cancer does not occur in isolation,” says Lawrence Shulman, MD, in commenting on the report. “It occurs in a human being, who may have other medical problems.”
By Richard Saltus Though quite curable when diagnosed early, kidney cancer in advanced stages can become a stubborn disease. However, the outlook for patients with metastatic kidney cancer has brightened in the past several years. Oncologists have added to their arsenal a number of designer drugs that attack molecular targets […]
For about 70 years, the standard treatment for patients with advanced prostate cancer was drugs that blocked male hormones feeding the tumor. If that stopped working and the disease progressed, oncologists turned to chemotherapy to kill the cancer cells. This timetable is about to change. Results of a clinical trial […]
Dana-Farber Cancer Institute’s Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH recently partnered with CancerConnect to answer questions about breast cancer therapies. Burstein and Mayer are breast oncologists in the Center for Breast Oncology at Dana-Farber’s Susan F. Smith Center for Women’s Cancers. Q: What medications are helpful […]
Ann LaCasce, MD, a medical oncologist in the Dana-Farber/Brigham and Women’s Cancer Center Adult Lymphoma Program, answered a variety of questions about Hodgkin and non-Hodgkin lymphoma during a live web chat hosted by Dana-Farber last month.
Experts with the U.S. Preventive Services Task Force (USPSTF) have recommended that current smokers and former-smokers who recently quit should undergo an annual low-dose CT scan to screen for lung cancer.
As 2013 comes to a close, we’re looking back at some of our favorite Insight posts from the last year. From inspiring patient stories to important research, here is our top 10 list:
By Robert Levy Treatments that unleash the body’s own disease-fighting cells against cancer – an approach known as immunotherapy – have been heralded as the “Breakthrough of the Year” by Science magazine.
An analysis of data from the decades-long Nurses’ Health Study revealed that women who ate a one-ounce serving of nuts – any kind of nuts – two or more times a week had a 35 percent lower risk of pancreatic cancer than women who abstained from them. That’s a significant […]
The 36th annual San Antonio Breast Cancer Symposium, which ran from Dec. 10-14, brought news of significant advances against a disease that strikes more than 230,000 women and 2,000 men in the United States each year. The more than 1,000 research papers presented by thousands of scientists and physicians ranged […]
While some people claim dairy products can prevent cancer, others argue that dairy could actually increase the cancer risk. There are also concerns that dairy can potentially spur growth in hormone-sensitive cancers, including some forms of ovarian and breast cancer. Is there a relationship between dairy and cancer? We consulted with the Dana-Farber/Brigham and Women’s Cancer Center […]
Approximately 173,000 people in the United States are living with Hodgkin lymphoma, or are in remission. Less common than non-Hodgkin lymphoma, Hodgkin lymphoma (sometimes referred to as Hodgkin’s lymphoma) is a malignancy of B lymphocytes, an important cell in the immune system. This malignant B cell is known as the […]
Lymphoma: How do we treat it? Where are future therapies headed? On Wednesday, Dec. 18, Ann LaCasce, MD, of the Dana-Farber/Brigham and Women’s Cancer Center Adult Lymphoma Program will answer your questions about lymphoma care in a live video webchat. The 45-minute chat starts at 1 p.m. EST and will […]
Despite the research, the promising new drugs, the many ongoing clinical trials, lung cancer remains a disease that affects too many people, too often. For patients and family members, the disease carries an added burden: a stigma that lung cancer and smoking go hand in hand, and that lung cancer […]
by Richard Saltus As recently as five years ago, progress in treating life-threatening malignant melanoma was slow. Since then, several molecularly targeted drugs have burst on the scene, and new strategies for awakening the immune system to attack the cancer cells have yielded dramatic long-term survival benefits for some patients. […]
As November marks Pancreatic Cancer Awareness Month, view the infographic below to learn more about the disease:
Current lymphoma therapies are a far cry from the mustard gas used more than 50 years ago. More treatment options, including ones that may be more effective and less toxic, are being studied in ongoing clinical trials. “Clinical trials really are the future of lymphoma treatment,” says Ann LaCasce, MD, […]
By Mark Pomerantz, MD There has been some uncertainty surrounding this question, but recent studies have demonstrated that having a vasectomy has no effect on the risk of prostate or testicular cancer. Older data – from studies tracking disease rates across broad population groups – suggested a modest connection, while […]
More than 228,000 new cases of lung cancer will be diagnosed in the United States in 2013, according to the National Cancer Institute (NCI). With November marking Lung Cancer Awareness Month, Pasi A. Jänne, MD, PhD, director of Dana-Farber’s Lowe Center for Thoracic Oncology, answers some key questions about the […]
Breast cancer is the most common cancer among American women, but only 5-10 percent of breast cancer cases are hereditary. Of those cases, roughly 20-25 percent are linked to mutations in the BRCA1 and BRCA2 genes (BRCA stands for BReast CAncer susceptibility). View the infographic below for more on the […]
Each year, Dana-Farber patients join clinicians, staff, and the Boston Red Sox to share their stories of inspiration and their belief in the research advances at Dana-Farber during the WEEI/NESN Jimmy Fund Radio-Telethon at Fenway Park. This year, nearly 100 patients, including Rayquan Fregeau, who used art and resources from […]
Dana-Farber Cancer Institute recently partnered with CancerConnect and Lakshmi Nayak, MD, to answer questions about brain cancer. Nayak is a neuro-oncologist in the Center for Neuro-Oncology at Dana-Farber/Brigham and Women’s Cancer Center and an instructor in neurology at Harvard Medical School. Q: There seems to be some progress concerning treatment […]
Breast cancer may develop in one part of the body, but it’s not just one disease. In fact, oncologists think of breast cancer as at least three different types of diseases. Triple-negative breast cancer (TNBC) describes breast cancer cells that do not have estrogen, progesterone, or HER2 receptors. It makes […]
By Alexi Wright, MD, MPH Although there are two main types of cervical cancer, known as adenocarcinoma and squamous cell carcinoma, they’ve generally been treated as one disease, with the same approach to treatment. In a recent study, my colleagues and I surveyed the DNA in both types of cervical […]
By Richard Saltus Physicians have long recognized that the same disease can behave differently from one patient to another, and that there is no one-size-fits-all treatment. In cancer, chemotherapy might dramatically shrink one lung tumor but prove ineffective against the same type of tumor in a different patient – even though […]
Dana-Farber Cancer Institute recently partnered with CancerConnect and Ursula Matulonis, MD, to answer questions about ovarian cancer. Experts in the Susan F. Smith Center for Women’s Cancers offer the latest research and treatment for this type of cancer. Watch one patient’s story. Q: Is taking curcumin recommended to prevent ovarian cancer from returning? […]
Lung cancer can be a frightening diagnosis. However, new treatment approaches and promising research trends have made the outlook for patients a little more optimistic, says David Jackman, MD, an oncologist in the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute.
By Ursula Matulonis, MD After a long period of slow progress, new knowledge about the genetics of ovarian cancer is leading to the development and testing of new therapies. Researchers at the Susan F. Smith Center for Women’s Cancers will soon be launching several phase 3 clinical trials testing drugs […]
When Angelina Jolie underwent a preventative double mastectomy earlier this year, this issue of cancer risk and genetics made front-page headlines. Jolie, who announced the operation in a New York Times op-ed, tested positive for the BRCA1 gene mutation and learned she had an 87 percent risk of developing breast […]
By Maura Perkins I can’t pinpoint when I started to get ovarian cancer symptoms. It was all very subtle and gradual. I was a healthy person. I ran, biked swam, hiked, and went to the gym regularly. A slight pain in my left side, difficulty digesting food, feeling of fullness, […]
By Melanie Graham During a child’s cancer therapy and recovery process, insomnia can often be viewed as only a side effect in the scope of treatment-related symptoms. However, there are many physical and psychological implications that develop when a child does not sleep well, says Eric Zhou, PhD, a clinical […]
More than 70 years ago, two pharmacologists began looking at mustard gas as a possible treatment for lymphoma. The chemical, used during World War I, lowered blood counts and destroyed lymph nodes in soldiers who were exposed to the gas. Two decades after the war, a thoracic surgeon named Gustav […]
The drug Avastin, when added to initial therapy for glioblastoma, can give patients a few extra months’ reprieve before their brain tumors start growing again, but does it make their quality of life better – or worse? That’s a matter of heated debate for doctors – and confusion for patients […]
By Ian Krop, MD, PhD Clinical trials are scientific studies in which new treatments – drugs, diagnostic procedures, and other therapies – are tested in people to find out if they are safe and effective. Nearly all cancer drugs in use today were tested in clinical trials.
By Wendy Chen, MD Dana-Farber Breast Oncology Center Susan F. Smith Center for Women’s Cancers Millions of women in the United States have sought treatment for fertility-related problems over the past 35 years. Because many of these treatments –including fertility drugs and in vitro fertilization (IVF) – use hormones to […]
By Eric Schuller If you recently learned you have cancer, donating a sample of your cancer tissue to science is probably the last thing on your mind. But it’s a topic that you might discuss with someone on your health care team, because cancer researchers often rely on donated tissue […]
Actress Angelina Jolie is no stranger to the headlines, but she stunned the world with her Op-Ed in The New York Times, in which she shared her very private decision to have a preventive double mastectomy after testing positive for the BRCA1 gene mutation. “I hope that other women can benefit […]
By Stephen Sallan, MD Today, three quarters or more of all childhood cancer patients will be cured of their disease, a higher percentage than ever before. And the numbers will only get better as we learn more about the biology of childhood cancers and develop new ways of treating them.
by Richard Saltus One of the oldest healing practices in the world, acupuncture is beginning to have a role in alleviating pain and discomfort associated with cancer and its treatments. Acupuncturists use fine needles to penetrate the skin and stimulate – manually or electrically – specific points on the body. Stimulation […]
Quite a few substances used in traditional medicine in China or other countries have received Food and Drug Administration (FDA) approval as cancer drugs… and their numbers are growing. Some examples are: Arsenic trioxide, made from arsenic sulfide ore, has been used therapeutically for more than 2,400 years. Following promising […]
One of the goals of the Rally for Medical Research, held in conjunction with the American Association for Cancer Research (AACR) 2013 Annual Meeting, earlier this month was to bring awareness to and education about the impact of the cuts in federal funding for medical research. Dana-Farber’s Kenneth C. Anderson, MD participated in the Rally. […]
by Robert Levy More than 18,000 cancer scientists from around the world are in Washington, D.C., this week for the annual meeting of the American Association for Cancer Research (AACR). The meeting serves as a forum for the presentation and discussion of the latest discoveries in cancer research. The meeting […]
by Richard Saltus Cells are like young children – they need a lot of guidance on how to behave. Your body’s cells are constantly getting that help – in the form of hormones, growth factors, and other chemicals telling them when to rest, grow, duplicate their DNA, divide, or […]
By Richard Saltus If the human genome – the complete set of DNA blueprints in a cell for building a human being — is truly “the book of life, ” as it has been called, then 99 percent of life’s book is gobbledygook. Only 1 percent of the DNA contains […]
By Edward J. Benz, Jr., MD The automatic budget cuts (or sequestration) that went into to effect as a result of the Budget Control Act of 2011, could have a chilling long-term effect on scientific research in the United States. The automatic cuts will slash 5.1 percent – or about […]
By William Hahn, MD, PhD Every year, hundreds of postdoctoral fellows and graduate students study cancer research at Dana-Farber under some of the world’s leading scientists. The Dana-Farber Postdoc and Graduate Student Affairs Office recently named the first recipient of its Mentor-of-the-Year Award: William Hahn, MD, PhD, the Institute’s deputy […]